Actos Lawsuit Verdict Prompts Pennsylvania Drug Lawyers to Comment

A jury in Louisiana has determined that Takeda Pharmaceuticals and Eli Lilly & Co. should pay billions of dollars for their role in covering up the serious bladder cancer risk associated with a diabetes drug called Actos. The defective drug lawyers of Levy, Baldante, Finney, Rubenstein, Cohen & Chizmar, P.C. are weighing in on the matter.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend
We have opened our doors to anyone who believes that Actos caused them to endure bladder cancer.

Philadelphia, PA (PRWEB) June 17, 2014

A jury has determined that Takeda Pharmaceuticals knowingly hid key insights about the dangers of Actos from regulators. As a result, Takeda and their partner company, Eli Lilly & Co., will now be tasked with paying $9 billion in a record-breaking verdict that could open the door for injured parties to receive ample compensation.

Over 2,700 lawsuits are currently awaiting resolution via In Re Actos (Pioglitazone) Products Liability Litigation, 11-md-02299, U.S. District Court, Western District of Louisiana (Lafayette). The plaintiffs in those lawsuits are persons who have alleged that they sustained bladder cancer after being prescribed Actos as a treatment for their diabetes or who lost loved ones due to the drug, which carries a generic name of pioglitazone.

Levy, Baldante, Finney, Rubenstein, Cohen & Chizmar, P.C., a Philadelphia personal injury law firm with practices in Pennsylvania and New Jersey, has been following these developments closely. Martin G. Rubenstein's position as the head of Levy Baldante’s defective drug litigation branch gives him a unique view of the proceedings. He wants all Actos patients to understand the role that Takeda played in not coming forward earlier with important information regarding the risks associated with Actos and what this means for patient health:

“Actos was approved in 1999, back when people were still worried about Y2K,” said Mr. Rubenstein. “And yet it wasn’t until 2011 that new labels outlining the bladder cancer risk were added to Actos, long after evidence pointed to a threat associated with the drug.”

The latest jury verdict is a boon to persons hoping to recuperate damages for the trying circumstances they were put through. Mr. Rubenstein hopes that this verdict can turn the tide in favor of all those who lost loved ones or whose lives were irrevocably altered by a dangerous drug.

“While the recent ruling will no doubt be contested by Takeda,” said Mr. Rubenstein, “this is a good sign for all those persons whose lives were upended by Actos. We have opened our doors to anyone who believes that Actos caused them to endure bladder cancer. This recent jury ruling means that all the litigation leading up to this point will not be in vain, but to take advantage of this momentum, all those who have yet to look into their legal options must do so now so that their rights can be protected.”

The law firm of Levy Baldante continues to assist those persons who believe that they were led astray by Actos. The firm is offering free consultations to all those who are interested in discussing the filing of an Actos-related lawsuit against Takeda.

The law firm of Levy, Baldante, Finney, Rubenstein, Cohen & Chizmar, P.C. represents several victims in the Actos litigation and is also a part of the multidistrict litigation taking place. The firm has been fighting for the rights of injured parties since its founding in the 1960s. Recognized by such organizations as Super Lawyers, the American Association for Justice, and the Trial Lawyers Associations of both Pennsylvania and New Jersey, Levy Baldante is dedicated to assisting persons injured by medical malpractice, automobile accidents, defective products, premises liability, and other instances of personal injury. Persons interested in filing an Actos lawsuit can click here.